Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emiplacel - Pluri

Drug Profile

Emiplacel - Pluri

Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; PLacental eXpanded cells; PLX PAD; PLX-PAD cell therapy

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pluristem Therapeutics
  • Developer Pluri; Tel-Aviv Ichilov Medical Center
  • Class Ischaemic heart disorder therapies; Mesenchymal stem cell therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic limb-threatening ischemia; Muscle injury
  • Phase II Intermittent claudication; SARS-CoV-2 acute respiratory disease
  • Phase I/II Graft-versus-host disease
  • No development reported Duchenne muscular dystrophy; Ischaemic heart disorders; Preeclampsia; Pulmonary arterial hypertension; Tendon injuries; Thromboangiitis obliterans

Most Recent Events

  • 08 Apr 2024 Pluri has patent protection for System and Methods for Immune Cells Expansion and Activation in Large Scale in the US
  • 06 Sep 2023 Pluristem completes a phase III trial for Muscle injury (In the elderly, In adults, In neonates, In infants, In children, In adolescents) in USA, Bulgaria, Denmark, Germany, United Kingdom and Israel (IM) (NCT03451916)
  • 07 Jun 2023 Pluristem terminates a phase II trial in SARS-COV-2 acute respiratory disease in USA (IM) due to the decision to bring the study to early clinical readout came in response to COVID-19's evolution as a disease, and the significant changes in the standard of care, leading to an increase in the severity of conditions of the intubated patients (NCT04389450)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top